These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551 [TBL] [Abstract][Full Text] [Related]
14. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection in pediatric liver recipients. A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment. Dussaix E; Wood C Transplantation; 1989 Aug; 48(2):272-4. PubMed ID: 2547257 [TBL] [Abstract][Full Text] [Related]
16. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation. Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976 [No Abstract] [Full Text] [Related]
17. Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir. Einsele H; Vallbracht A; Friese M; Schmidt H; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G Bone Marrow Transplant; 1988 Nov; 3(6):607-17. PubMed ID: 2850830 [TBL] [Abstract][Full Text] [Related]
18. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871 [No Abstract] [Full Text] [Related]
19. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB Transplant Proc; 1991 Feb; 23(1 Pt 2):1357-60. PubMed ID: 1846464 [No Abstract] [Full Text] [Related]
20. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival. Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]